The market environment continued challenging and Verkkokauppa.
Main points in SRV’s Q1 report related to the write-downs of holdings relating to Russia and Fennovo...
Redeye sees a very solid Q1 from Addnode, with record-high margins in all three Divisions.
Redeye has a positive view of Orexo after the Q1 report, but we see a challenge to stabilising the Z...
Redeye returns with an in-depth take on the Q1 report following the conference call and discussion w...
Redeye bibehåller BioArctics värdering på 250 kronor per aktie efter rapporten.
Adj. EBITA 12% above our expectations Q2’22 should be boosted by heating projects… …and strong L12m ...
Redeye sees a solid Q1 report from Sdiptech on the group level.
Redeye sees a strong Q1’22 report from Stille, where sales in the operating tables segment surprised...
Redeye comments on Medivir’s first quarter report.
Redeye retains its positive view on Proact following a mixed Q1 report with a solid outlook.
Redeye changes our short-term estimates on the back of a challenging environment for Tagmaster.
Redeye does limited changes to estimates following Evolution’s Q1-results which came in close to our...
Sales 0% vs ABGSCe Adj. EBITA 12% vs ABGSCe Europe and RoW driving growth, Nordics more muted Q1’2...
Redeye concludes that Q1 was weaker than Redeye estimates.
Sales up 29% y-o-y, but pressured profitability Write down of account receivable of SEK 15m due to U...
Redeye has a positive initial take on the Q1 report – SaaS KPIs confirm that Artificial Solutions is...
Biovica has now submitted the updated FDA application.
Sdiptech delivered a solid Q1 report, in line with our expectations on EBITA*, but -4% on the report...
Redeye states that the Q4 report was mixed with better sales development and weaker profitability.
